InspireMD Announces Pricing of $37.5 Million Public Offering

MIAMI, Nov. 13, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the pricing of its previously announced underwritten public offering of (i) 7,342,308 shares of its common stock, (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase 50,350,000 shares of its common stock, and (iii) accompanying common warrants to purchase 43,269,231 shares of its common stock (or pre-funded warrants in lieu thereof). All securities in the offering are being offered by InspireMD.